CEREBROSPINAL-FLUID INHIBITS ALZHEIMER BETA-AMYLOID FIBRIL FORMATION IN-VITRO

被引：59

作者：

WISNIEWSKI, T ^{[1
]}

CASTANO, E ^{[1
]}

GHISO, J ^{[1
]}

FRANGIONE, B ^{[1
]}

机构：

[1] NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016

来源：

ANNALS OF NEUROLOGY | 1993年 / 34卷 / 04期

关键词：

D O I：

10.1002/ana.410340422

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Alzheimer's disease is characterized by the deposition of beta-protein (Abeta) as amyloid. Recently, it was found that Abeta is a normal component of serum and cerebrospinal fluid. Synthetic peptides homologous to Abeta form amyloid-like fibrils spontaneously in water or physiological solutions. Using a peptide homologous to Abeta1-40, we find that fibril formation is inhibited by the presence of cerebrospinal fluid.

引用

页码：631 / 633

页数：3

共 50 条

[31] BETA-AMYLOID NEUROTOXICITY REQUIRES FIBRIL FORMATION AND IS INHIBITED BY CONGO RED
LORENZO, A
YANKNER, BA
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (25) : 12243 - 12247
[32] Crocetin inhibits beta-amyloid fibrillization and stabilizes beta-amyloid oligomers
Ahn, Joon Ho
Hu, Yang
Hernandez, Michael
Kim, Jin Ryoun
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 414 (01) : 79 - 83
[33] Kinetic analysis of beta-amyloid fibril elongation
Cannon, MJ
Williams, AD
Wetzel, R
Myszka, DG
ANALYTICAL BIOCHEMISTRY, 2004, 328 (01) : 67 - 75
[34] Salvianolic acid B inhibits fibril formation and neurotoxicity of amyloid beta-protein in vitro
Tang, MK
Zhang, JT
ACTA PHARMACOLOGICA SINICA, 2001, 22 (04): : 380 - 384
[35] Cerebrospinal Fluid Beta-Amyloid Concentration and Clinical and Radiographic Manifestations of Cerebral Amyloid Angiopathy
Alten, Baris
Gokcal, Elif
Warren, Andrew
van Veluw, Susanne J.
Kozberg, Mariel
Gurol, M. Edip
Viswanathan, Anand
Greenberg, Steven M.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (05):
[36] IN-VITRO AMYLOID FIBRIL FORMATION FROM ALPHA(1)-ANTITRYPSIN
JANCIAUSKIENE, S
CARLEMALM, E
ERIKSSON, S
BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1995, 376 (02): : 103 - 109
[37] Treatment with selective muscarinic MI agonist talsaclidine lowers the cerebrospinal fluid beta-amyloid levels in Alzheimer patients
Hager, K
Magdalena, A
Raschig, A
Müller-Spahn, E
Eschweiler, G
Heuser, I
Hampel, H
Müller-Thomsen, T
Oertel, W
Wienrich, M
Signorell, A
Gonzalez-Agosti, C
Nitsch, RM
Hock, C
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2004, 37 : 6 - 7
[38] Rapid multiplexed detection of beta-amyloid and total-tau as biomarkers for Alzheimer's disease in cerebrospinal fluid
Song, Chao
Deng, Pan
Que, Long
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2018, 14 (06) : 1845 - 1852
[39] Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging
Schroder, J
Pantel, J
Ida, N
Essig, M
Hartmann, T
Knopp, MV
Schad, LR
Sandbrink, R
Sauer, H
Masters, CL
Beyreuther, K
MOLECULAR PSYCHIATRY, 1997, 2 (06) : 505 - 507
[40] SOLUBLE DERIVATIVES OF THE BETA-AMYLOID PROTEIN-PRECURSOR IN CEREBROSPINAL-FLUID - ALTERATIONS IN NORMAL AGING AND IN ALZHEIMERS-DISEASE
PALMERT, MR
USIAK, M
MAYEUX, R
RASKIND, M
TOURTELLOTTE, WW
YOUNKIN, SG
NEUROLOGY, 1990, 40 (07) : 1028 - 1034

← 1 2 3 4 5 →